Generic User Fee Waivers Dropped In Latest House Draft Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Provision allowing generic drug fee waivers in shortage situations was removed in new House user fee draft, but proposals for a new antibacterial approval pathway and breakthrough designation were not included.
You may also be interested in...
GDUFA Facility Fees Should Be Waived Until First ANDA Approved, Petition Argues
Bangladesh-based Square Pharmaceuticals says the fees are burdensome for first-time filers, given long approval times, but the firm’s citizen petition strategy may further delay approval of its ANDA.
Antibiotics Approval Changes GAINing Acceptance; PDUFA May Not Get LPADed Out
Rep. Waxman is expected to bring up the Limited Population Antibacterial Drug proposal during an April 18 hearing, but it was not included in the latest House user fee discussion draft.
Drug Shortage Legislation: Sen. Blumenthal Calls For More Extensive Effort
Democratic Senator has terse exchange with FDA at hearing and says Congress must do more than what is already in pending legislation. Blumenthal said he is willing to consider the Generic Pharmaceutical Association proposal calling for an independent third party to compile supplier data and predict coming shortages.